Cover Image

TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).

Leishmania (Viannia) parasites present particular challenges, as human and murine immune responses to infection are distinct from other Leishmania species, indicating a unique interaction with the host. Further, vaccination studies utilizing small animal models indicate that modalities and antigens...

Full description

Saved in:

Bibliographic Details
Main Authors:	Asha Jayakumar (Author), Tiago M Castilho (Author), Esther Park (Author), Karen Goldsmith-Pestana (Author), Jenefer M Blackwell (Author), Diane McMahon-Pratt (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2011-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Heterologous Prime-boost COVID-19 Vaccination
by: Vishal R. Tandon, et al.
Published: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
by: Om Prakash Choudhary, et al.
Published: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
by: Tesfaye Gelanew, et al.
Published: (2023)

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults
by: Macaya Douoguih, et al.
Published: (2016)

Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon.
by: Jorge Augusto de Oliveira Guerra, et al.
Published: (2011)

Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection
by: Ming Zhang, et al.
Published: (2017)

Sampling is decisive to determination of Leishmania (Viannia) species.
by: Maxy B De Los Santos, et al.
Published: (2024)

Toxicity and Anti-promastigote Activity of Benzoxazinoid Analogs Against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) infantum
by: Gilberto de Sousa, et al.
Published: (2020)

A Heterologous Multiepitope DNA Prime/Recombinant Protein Boost Immunisation Strategy for the Development of an Antiserum against Micrurus corallinus (Coral Snake) Venom.
by: Henrique Roman Ramos, et al.
Published: (2016)

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review
by: Jingjing Lv, et al.
Published: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022)

Coinfection of Leishmania (Viannia) braziliensis and Streptococcus pneumoniae in Multiple Cutaneous Lesions.
by: Paulo R Cortes, et al.
Published: (2016)

Genetic diversity and population structure of Leishmania (Viannia) braziliensis in the Peruvian jungle.
by: Maxy B De Los Santos, et al.
Published: (2022)

Genetic diversity and population structure of Leishmania (Viannia) braziliensis in the Peruvian jungle
by: Maxy B. De los Santos, et al.
Published: (2022)

Human macrophage response to L. (Viannia) panamensis: microarray evidence for an early inflammatory response.
by: Carolina Ramírez, et al.
Published: (2012)

Heterologous vaccine interventions: boosting immunity against future pandemics
by: Daniela Marín-Hernández, et al.
Published: (2021)

Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review
by: Ishan Garg, et al.
Published: (2022)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
by: Georgi Shukarev, et al.
Published: (2017)

Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
by: Houreratou Barry, et al.
Published: (2024)

Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
by: Diego M Santos, et al.
Published: (2014)

An Innovative Field-Applicable Molecular Test to Diagnose Cutaneous Leishmania Viannia spp. Infections.
by: Omar A Saldarriaga, et al.
Published: (2016)

In-depth quantitative proteomics uncovers specie-specific metabolic programs in Leishmania (Viannia) species.
by: Nathalia Pinho, et al.
Published: (2020)

High Selectivity of 8-Hydroxyquinoline on <i>Leishmania (Leishmania)</i> and <i>Leishmania (Viannia)</i> Species Correlates with a Potent Therapeutic Activity In Vivo
by: Sarah Kymberly Santos de Lima, et al.
Published: (2023)

An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine
by: Hana M El Sahly, et al.
Published: (2020)

Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia.
by: Olga Lucía Fernández, et al.
Published: (2014)

Population structure and evidence for both clonality and recombination among Brazilian strains of the subgenus Leishmania (Viannia).
by: Katrin Kuhls, et al.
Published: (2013)

Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species.
by: Daniel Rodriguez-Pinto, et al.
Published: (2012)

Novel prime-boost vaccine strategies against HIV-1
by: Jean-Louis Excler, et al.
Published: (2019)

Differential Recruitment of Dendritic Cells Subsets to Lymph Nodes Correlates with a Protective or Permissive T-Cell Response during Leishmania (Viannia) Braziliensis or Leishmania (Leishmania) Amazonensis Infection
by: A. K. Carvalho, et al.
Published: (2016)

Correction: Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Published: (2014)

Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis.
by: Olga Lucía Fernández, et al.
Published: (2024)

New insights on taxonomy, phylogeny and population genetics of Leishmania (Viannia) parasites based on multilocus sequence analysis.
by: Mariana C Boité, et al.
Published: (2012)

First Human Cases of Leishmania (Viannia) lainsoni Infection and a Search for the Vector Sand Flies in Ecuador.
by: Hirotomo Kato, et al.
Published: (2016)

Infectiousness of Sylvatic and Synanthropic Small Rodents Implicates a Multi-host Reservoir of Leishmania (Viannia) braziliensis.
by: Maria S Andrade, et al.
Published: (2015)

Natural infections of Pintomyia verrucarum and Pintomyia maranonensis by Leishmania (Viannia) peruviana in the Eastern Andes of northern Peru.
by: Hirotomo Kato, et al.
Published: (2021)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023)

Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older
by: Yingping Chen, et al.
Published: (2023)

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
by: Peter Nordström, et al.
Published: (2021)

Cellular growth and mitochondrial ultrastructure of leishmania (Viannia) braziliensis promastigotes are affected by the iron chelator 2,2-dipyridyl.
by: Camila Mesquita-Rodrigues, et al.
Published: (2013)

Dynamics of American tegumentary leishmaniasis in a highly endemic region for Leishmania (Viannia) braziliensis infection in northeast Brazil.
by: Juliana Silva, et al.
Published: (2017)